Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keum, Y.-S.
Right arrow Articles by Kong, A.-N. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keum, Y.-S.
Right arrow Articles by Kong, A.-N. T.
[Cancer Research 66, 8804-8813, September 1, 2006]
© 2006 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Mechanism of Action of Sulforaphane: Inhibition of p38 Mitogen-Activated Protein Kinase Isoforms Contributing to the Induction of Antioxidant Response Element–Mediated Heme Oxygenase-1 in Human Hepatoma HepG2 Cells

Young-Sam Keum1, Siwang Yu1, Peter Pil-Jae Chang1, Xiaoling Yuan1, Jung-Hwan Kim1, Changjiang Xu1, Jiahuai Han2, Anupam Agarwal3 and Ah-Ng Tony Kong1

1 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey; 2 Department of Immunology, The Scripps Research Institute, La Jolla, California; and 3 Department of Medicine, Nephrology Research and Training Center, University of Alabama, Birmingham, Alabama

Requests for reprints: Ah-Ng Tony Kong, Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854. Phone: 732-445-3831, ext. 228; Fax: 732-445-3134; E-mail: KongT{at}rci.rutgers.edu.

Exposure of sulforaphane to HepG2 cells increased heme oxygenase-1 (HO-1) expression by activating antioxidant response element (ARE) through induction of Nrf2 and suppression of Kelch-like ECH-associated protein 1 (Keap1). Using human HO-1 promoter reporter plasmids and ChIP assay, we have identified that sulforaphane transcriptionally activated the upstream ARE-rich enhancer region, located at –9.0 kb upstream human HO-1 promoter. Induction of HO-1 by sulforaphane was attenuated by overexpression of mutant Nrf2 plasmid in HepG2 cells and totally abolished in Nrf2 knockout mouse embryonic keratinocytes and fibroblasts. Overexpression of individual p38 mitogen-activated protein (MAP) kinase (MAPK) isoforms also suppressed constitutive as well as sulforaphane- or Nrf2-induced ARE-dependent gene expression. Among the upstream kinases, although MKK3 was not involved in suppression of ARE by any of p38 MAPK isoforms, MKK6 selectively suppressed ARE by p38{gamma} or p38{delta}, but not by p38{alpha} or p38ß. Importantly, sulforaphane not only activated MAP/extracellular signal-regulated kinase (ERK) kinases 1/2 and ERK1/2, but also strongly suppressed anisomycin-induced activation of p38 MAPK isoforms by blocking phosphorylation of upstream kinases, MKK3/6. Finally, we found that stimulation of p38 MAPK isoforms phosphorylated purified Nrf2 protein and caused an increase in the interaction between Nrf2 and Keap1 in vitro and the suppression of Nrf2 translocation into the nucleus. Collectively, our results indicate that transcriptional activation of Nrf2/ARE is critical in sulforaphane-mediated induction of HO-1, which can be modulated in part by the blockade of p38 MAPK signaling pathway. In addition, our study shows that p38 MAPK can phosphorylate Nrf2 and promotes the association between Nrf2 and Keap1 proteins, thereby potentially inhibiting nuclear translocation of Nrf2. (Cancer Res 2006; 66(17): 8804-13)




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. A. Alaoui-Jamali, T. A. Bismar, A. Gupta, W. A. Szarek, J. Su, W. Song, Y. Xu, B. Xu, G. Liu, J. Z. Vlahakis, et al.
A Novel Experimental Heme Oxygenase-1-Targeted Therapy for Hormone-Refractory Prostate Cancer
Cancer Res., October 15, 2009; 69(20): 8017 - 8024.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Naidu, V. Vijayan, S. Santoso, T. Kietzmann, and S. Immenschuh
Inhibition and Genetic Deficiency of p38 MAPK Up-Regulates Heme Oxygenase-1 Gene Expression via Nrf2
J. Immunol., June 1, 2009; 182(11): 7048 - 7057.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H.-Y. Cho, F. Imani, L. Miller-DeGraff, D. Walters, G. A. Melendi, M. Yamamoto, F. P. Polack, and S. R. Kleeberger
Antiviral Activity of Nrf2 in a Murine Model of Respiratory Syncytial Virus Disease
Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 138 - 150.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Xue, Q. Qian, A. Adaikalakoteswari, N. Rabbani, R. Babaei-Jadidi, and P. J. Thornalley
Activation of NF-E2-Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular Disease
Diabetes, October 1, 2008; 57(10): 2809 - 2817.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C.-W. Lin, S.-C. Shen, W.-C. Hou, L.-Y. Yang, and Y.-C. Chen
Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9
Mol. Cancer Ther., May 1, 2008; 7(5): 1195 - 1206.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
H. Zhang and H. J. Forman
Acrolein Induces Heme Oxygenase-1 through PKC-{delta} and PI3K in Human Bronchial Epithelial Cells
Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 483 - 490.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. G. Abraham and A. Kappas
Pharmacological and Clinical Aspects of Heme Oxygenase
Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Pugazhenthi, L. Akhov, G. Selvaraj, M. Wang, and J. Alam
Regulation of heme oxygenase-1 expression by demethoxy curcuminoids through Nrf2 by a PI3-kinase/Akt-mediated pathway in mouse beta-cells
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E645 - E655.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.